Only the United States and New Zealand allow direct-to-consumer advertising (DTCA) of prescription medicines. The authors outline the evolution of DTCA in New Zealand and the development of an industry-based self-regulatory system. The authors examine the concerns raised about self-regulation of DTCA, evaluate the evidence related to these, and identify issues that require further attention to strengthen the model currently used. The authors conclude that a self-regulatory approach, complemented by parallel government monitoring, provides an efficient, responsive system for promoting responsible and ethical DTCA.
Advertising Standards Authority (2002), “Advertising Standards Authority Inc,” (accessed May 20, 2002), [available at http://www.asa.co.nz/asainc.htm].
3.
American College of Physicians and the American Society of Internal Medicine (1998), “Direct to Consumer Advertising for Prescription Drugs,” (accessed June 8, 2001), [available at http://www.acponline.org/hpp/pospaper/dtcads.htm].
4.
BasaraLisa R. (1996), “The Impact of a DTC Prescription Medicine Advertising Campaign on New Prescription Volume,”Drug Information Journal, 30(3), 715–29.
5.
BoddewynJean (1985), “Advertising Self-Regulation: Private Government and Agent of Public Policy,”Journal of Public Policy & Marketing, 4, 129–41.
6.
ConeySandra (2002), “Direct-to-Consumer Advertising of Prescription Pharmaceuticals: A Consumer Perspective from New Zealand,”Journal of Public Policy & Marketing, 21(Fall), 213–23.
7.
DavisJoel (2000), “Riskier Than We Think? The Relationship Between Risk Statement Completeness and Perceptions of Direct to Consumer Advertised Prescription Drugs,”Journal of Health Communication, 5(4), 349–69.
8.
DesselleShane, and AparasuRajender (2000), “Attitudinal Dimensions That Determine Pharmacists’ Decisions to Support Direct to Consumer Advertising of Prescription Medicines,”Drug Information Journal, 34(1), 103–14.
9.
EverettStephen (1991), “Lay Audience Response to Prescription Drug Advertising,”Journal of Advertising Research, 31(2), 43–49.
10.
GalballyRhonda (2001), National Competition Review of Drugs, Poisons and Controlled Substances Legislation Options Paper, (accessed December 10, 2001), [available at http://www.health.gov.au/tga/docs/pdf/discuss.pdf].
11.
HarkerDebra (1998), “Achieving Acceptable Advertising: An Analysis of Advertising Regulation in 5 Countries,”International Marketing Review, 15(2), 101–18.
12.
HoekJanet (1999), An Evaluation of the Therapeutic Advertising Advisory Service. Report commissioned by the Association of New Zealand Advertisers, Department of Marketing, Massey University (November).
13.
HoekJanet (2000), An Evaluation of the Therapeutic Advertising Advisory Service. Report commissioned by the Association of New Zealand Advertisers, Department of Marketing, Massey University (October).
14.
HoekJanet (2002), An Evaluation of the Therapeutic Advertising Pre-Vetting Service. Report commissioned by the Association of New Zealand Advertisers, Department of Marketing, Massey University (April).
15.
HoekJanet, GendallPhilip, and FeethamPam (2001), “Could Less Be More? An Analysis of Direct to Consumer Advertising of Prescription Medicines,”Marketing Bulletin, 12, (accessed September 12, 2002), [available at http://marketing-bulletin.massey.ac.nz/contents1.asp].
MansfieldPeter (1999), “Report on DTC Pharmaceutical Promotion for PHARMAC,” (accessed May 14, 2002), [available at http://www.healthyskepticism.org/].
21.
Ministry of Health (2000), Direct to Consumer Advertising of Prescription Medicines in New Zealand: A Discussion Paper, (November). Wellington, New Zealand: Ministry of Health.
Ministry of Health (2001b), Report on the Review of Direct to Consumer Advertising of Prescription Medicines in New Zealand, (August). Wellington, New Zealand: Ministry of Health.
24.
MintzesBarbara (2001), Pills, Persuasion and Public Health Policies: Report of an Expert Survey on Direct to Consumer Advertising of Prescription Drugs in Canada, The United States and New Zealand, (June). Vancouver, Canada: Centre for Health Services and Public Policy, University of British Columbia.
25.
MintzesBarbara (2002), “Direct to Consumer Advertising Is Medicalising Normal Human Experience,”British Medical Journal, 324(April 13), 908–909.
26.
MintzesBarbara, BarerMorris, KravitzRichard, KazanjianArminee, BassettKen, LexchinJoel, EvansRobert, PanRichard, and MarionStephen (2002), “Influence of Direct to Consumer Pharmaceutical Advertising and Patients’ Requests on Prescribing Decisions: Two Site Cross Sectional Survey,”British Medical Journal, 324(February 2), 278–79.
27.
MorrisLouis (1986), “The Attitudes of Consumers Toward Direct Advertising of Prescription Drugs,”Public Health Reports, 101(1), 82–89.
28.
MorrisLouis, BrinbergDavid, KlimbergRonald, RiveraCarole, and MillsteinLloyd (1986), “Consumer Attitudes About Advertisements of Medicinal Drugs,”Social Science Medicine, 22(6), 629–38.
29.
MorrisLouis, and GriffinJoseph (1992), “The Evolving Role of FDA in Prescription Drug Promotion,”Journal of Drug Issues, 22(2), 245–57.
30.
MossinghoffGerald (1992), “Pharmaceutical Manufacturers and Self-Regulation of Drug Advertising and Promotion,”Journal of Drug Issues, 22(2), 235–44.
31.
New Zealand Medical Association (2001), Submission on the Direct to Consumer Advertising of Prescription Medicines in New Zealand.Wellington, New Zealand: New Zealand Medical Association.
32.
Pharmaceutical Management Agency (2001a), “Public Has a Right to Balanced Information on Medicines,” press release, (April 18), (accessed June 8), [available at www.pharmac.govt.nz].
33.
Pharmaceutical Management Agency (2001b), Submission on Ministry of Health Review of Direct to Consumer Advertising.Wellington, New Zealand: Pharmaceutical Management Agency Limited.
34.
PinesWayne (1997), “Three Principles That Govern FDA Advertising and Promotion Regulation,”Drug Information Journal, 31(1), 137–42.
35.
PrattPeter (1998), Summary Report: Assessment of Regulatory Compliance for Medicines Advertised Direct to Consumers.Wellington, New Zealand: MedSafe, Ministry of Health.
36.
PrattPeter (2000), Summary Report: Assessment of Regulatory Compliance for Medicines Advertised Direct to Consumers.Wellington, New Zealand: MedSafe, Ministry of Health.
Royal College of New Zealand General Practitioners (2000), “GPs Welcome DTC Advertising Review,” media release, (October 9), (accessed September 12, 2002), [available at http://www.rnzcgp.org.nz/Media%20Releases/].
SheffetMary Jane, and KoppSteven (1990), “Advertising Prescription Drugs to the Public: Headache or Relief?”Journal of Public Policy & Marketing, 9, 42–61.
42.
Social Audit, (2000), “Letter to EC Consultation on Advertising and Electronic Commerce,” (accessed December 10, 2001), [available at http://www.socialaudit.org.uk/5111-002.htm].
43.
SternPhilip (1997), “Long Run Loyalty,”Marketing & Research Today, 25(2), 70–78.
WiggsGlen (2002), Executive Director, Advertising Standards Authority, personal communications, (July 1 and 2).
46.
WilkesMichael, BellRobert, and KravitzRichard (2000), “D-T-C Prescription Drug Advertising: Trends, Impact and Implications,”Health Affairs, 19(2), 110–28.
47.
Women's Health Action Trust (2001), “Direct-to-Consumer-Advertising of Prescription Medicines in New Zealand: Submission on Ministry of Health Discussion Paper,” (accessed July 1, 2002), [available at http://www.womens-health.org.nz/dtc.htm#dtcsub].
